Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep;19(9):577-592.
doi: 10.1038/s41569-022-00676-y. Epub 2022 Mar 22.

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Jan Borén  1 , Marja-Riitta Taskinen  2 , Elias Björnson  3 , Chris J Packard  4
Affiliations
Review

Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

Jan Borén et al. Nat Rev Cardiol. 2022 Sep.

Abstract

Accumulating evidence points to the causal role of triglyceride-rich lipoproteins and their cholesterol-enriched remnants in atherogenesis. Genetic studies in particular have not only revealed a relationship between plasma triglyceride levels and the risk of atherosclerotic cardiovascular disease, but have also identified key proteins responsible for the regulation of triglyceride transport. Kinetic studies in humans using stable isotope tracers have been especially useful in delineating the function of these proteins and revealing the hitherto unappreciated complexity of triglyceride-rich lipoprotein metabolism. Given that triglyceride is an essential energy source for mammals, triglyceride transport is regulated by numerous mechanisms that balance availability with the energy demands of the body. Ongoing investigations are focused on determining the consequences of dysregulation as a result of either dietary imprudence or genetic variation that increases the risk of atherosclerosis and pancreatitis. The identification of molecular control mechanisms involved in triglyceride metabolism has laid the groundwork for a 'precision-medicine' approach to therapy. Novel pharmacological agents under development have specific molecular targets within a regulatory framework, and their deployment heralds a new era in lipid-lowering-mediated prevention of disease. In this Review, we outline what is known about the dysregulation of triglyceride transport in human hypertriglyceridaemia.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ginsberg, H. N. et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur. Heart J. 42, 4791–4806 (2021). - PubMed - PMC - DOI
    1. Emerging Risk Factors, C. et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993–2000 (2009). - DOI
    1. Chapman, M. J. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345–1361 (2011). - PubMed - PMC - DOI
    1. Austin, M. A. Plasma triglyceride and coronary heart disease. Arterioscler. Thromb. 11, 2–14 (1991). - PubMed - DOI
    1. Tall, A. R. HDL in morbidity and mortality: a 40+ year perspective. Clin. Chem. 67, 19–23 (2021). - PubMed - DOI

Publication types

LinkOut - more resources